Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML. (2019)
Attributed to:
Elucidation of cellular and molecular mechanisms of lymphoma induction and evolution to identify therapeutic targets
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1084/jem.20181276
PubMed Identifier: 30890554
Publication URI: http://europepmc.org/abstract/MED/30890554
Type: Journal Article/Review
Volume: 216
Parent Publication: The Journal of experimental medicine
Issue: 4
ISSN: 0022-1007